OUR SERVICES

Spravato® (Esketamine) Treatment

An FDA-approved nasal spray for treatment-resistant depression, administered in-office under observation.

WHAT IS SPRAVATO?

A different kind of relief.

Spravato (esketamine) is an FDA-approved nasal spray for treatment-resistant depression in adults.

It works similarly to ketamine — but interacts more strongly with NMDA receptors, proteins in the brain that play a key role in how these treatments help lift depression.

Highly effective for treating TRD and MDSI

Backed by most insurance

Get Started

Why patients choose Spravato

Accepted by most major insurance providers — including Aetna, Cigna, BCBS of Mass, Humana, and MassHealth.

Clinically shown to work quickly — many patients notice a difference within days to a few weeks, rather than the months typical of oral antidepressants.

Individual results vary. We'll verify your specific insurance benefits before starting treatment.

WHO CAN BENEFIT

What Spravato is approved to treat.

Spravato is specifically approved for patients with a formal diagnosis of one of the following. If neither applies to you, our IV ketamine services may be a better fit — we'll help you figure out which during your consultation.

Treatment-Resistant Depression

You've tried at least two standard antidepressants at an adequate dose and duration with no significant benefit.

MDD with Suicidal Ideation

A clinical diagnosis of Major Depressive Disorder, with risk of suicide identified by a registered clinician.

COVERAGE

Spravato is covered by the following insurance providers.

Aetna Cigna BCBS of Mass Humana MassHealth

HOW SPRAVATO HELPS

Relief that works differently.

Rapid relief for patients who haven't responded to traditional antidepressants, often within hours to weeks rather than months.

FDA-approved for treatment-resistant depression and MDD with suicidal ideation — reviewed and confirmed safe and effective for its intended use.

Mostly covered by insurance — we're in-network with several leading providers to help keep costs manageable.

Request a Consultation

How Spravato helps patients at Emerge Therapy

FREQUENTLY ASKED QUESTIONS

Your Spravato questions, answered.

Yes. Spravato was FDA approved for treatment-resistant depression in 2019, and for Major Depressive Disorder with acute suicidal ideation in 2020. It's the only FDA-approved nasal spray for adults with these two forms of challenging-to-treat depression.

Most insurance plans do cover Spravato. We're in-network with several of the region's leading insurance providers, including Aetna, Cigna, BCBS of Mass, Humana, and MassHealth. Not sure if you're covered? We'll verify your benefits before starting treatment.

Spravato is a self-administered nasal spray, given in-office under observation by our clinical team, typically 1–2 times per week depending on where you are in treatment.

Spravato is approved for adults with a formal diagnosis of treatment-resistant depression, or Major Depressive Disorder with suicidal ideation. If you don't meet either criteria, our IV ketamine services may be a better fit.

Not exactly. Spravato is made of esketamine, a molecule derived from ketamine. It works similarly, but interacts more strongly with NMDA receptors in the brain, which is part of how it produces its effects.

Let's get you started.

During your telehealth consult, we'll review your symptoms, verify your insurance, and help you decide if Spravato is right for you.